Bristol Myers bought InhiBitex for more than $2Billion per WSJ 01-07-2012
For the next year or so this doesn't matter. Vertex sales numbers have been exploding (9-30-11) with last quarterly numbers coming soon. Analyst will have to take note. Profits will show up sooner or later. These guys have the first move advantage. None of competition are out of phase II yet which means Vertex will build sales and profits for shareholders. Enjoy the ride.